Bionoid Pharma Stock Fundamentals
| BINP Stock | USD 0.23 0.00 0.00% |
Bionoid Pharma fundamentals help investors to digest information that contributes to Bionoid Pharma's financial success or failures. It also enables traders to predict the movement of Bionoid Pink Sheet. The fundamental analysis module provides a way to measure Bionoid Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bionoid Pharma pink sheet.
Bionoid |
Bionoid Pharma Company Shares Outstanding Analysis
Bionoid Pharma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Bionoid Pharma Shares Outstanding | 42.28 M |
Most of Bionoid Pharma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bionoid Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Bionoid Pharma has 42.28 M of shares currently outstending. This is 76.58% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all United States stocks is 92.61% higher than that of the company.
Bionoid Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bionoid Pharma's current stock value. Our valuation model uses many indicators to compare Bionoid Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bionoid Pharma competition to find correlations between indicators driving Bionoid Pharma's intrinsic value. More Info.Bionoid Pharma is rated fifth in return on asset category among its peers. It is rated second in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bionoid Pharma's earnings, one of the primary drivers of an investment's value.Bionoid Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bionoid Pharma's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bionoid Pharma could also be used in its relative valuation, which is a method of valuing Bionoid Pharma by comparing valuation metrics of similar companies.Bionoid Pharma is currently under evaluation in shares outstanding category among its peers.
Bionoid Fundamentals
| Return On Asset | -1.64 | |||
| Operating Margin | (4.22) % | |||
| Current Valuation | 3.81 M | |||
| Shares Outstanding | 42.28 M | |||
| Price To Sales | 540.76 X | |||
| Revenue | 92.26 K | |||
| Gross Profit | 47.48 K | |||
| EBITDA | (385.71 K) | |||
| Net Income | (1.62 M) | |||
| Cash And Equivalents | 127 | |||
| Total Debt | 64.5 K | |||
| Current Ratio | 0.07 X | |||
| Book Value Per Share | (29.92) X | |||
| Cash Flow From Operations | (357.62 K) | |||
| Earnings Per Share | (46.27) X | |||
| Beta | -2.12 | |||
| Market Capitalization | 42.28 M |
About Bionoid Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bionoid Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionoid Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionoid Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Bionoid Pharma Inc. engages in the hemp cultivation business. Bionoid Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 5 people.
Pair Trading with Bionoid Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionoid Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionoid Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Bionoid Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionoid Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionoid Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionoid Pharma to buy it.
The correlation of Bionoid Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionoid Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionoid Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionoid Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Bionoid Pink Sheet Analysis
When running Bionoid Pharma's price analysis, check to measure Bionoid Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionoid Pharma is operating at the current time. Most of Bionoid Pharma's value examination focuses on studying past and present price action to predict the probability of Bionoid Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionoid Pharma's price. Additionally, you may evaluate how the addition of Bionoid Pharma to your portfolios can decrease your overall portfolio volatility.